This is a routine governance filing with no immediate trading implications. Monitor for any future executive departures or change-of-control events that would trigger the severance provisions, but no catalyst is present today.
Price Chart
Executive Summary
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the CEO (Tier 1), other Section 16 officers (Tier 2), and VPs+ (Tier 3). The plan provides cash severance of 18/12/6 months' base salary outside a change of control, and 24/18/9 months' salary plus target bonus, full equity acceleration, and COBRA payments upon a qualifying termination during a change of control period. This is a routine adoption of a standardized severance framework that supersedes prior individual agreements, with no departure or appointment of any officer.
Key Facts
- Plan adopted June 5, 2026, approved by Compensation Committee
- CEO (Tier 1) gets 18 months base salary severance outside CIC, 24 months plus target bonus and full equity vesting during CIC period
- Other Section 16 officers (Tier 2) get 12 months base salary outside CIC, 18 months plus target bonus and full equity vesting during CIC period
- VPs+ (Tier 3) get 6 months base salary outside CIC, 9 months plus target bonus and full equity vesting during CIC period
- Plan supersedes all prior severance arrangements in employment agreements
- No officer departures or appointments were announced
Financial Impact
No specific dollar amounts disclosed; severance is formula-based on base salary and target bonus. The plan is unfunded and paid from general assets.
Risk Factors
- No material risks identified from this filing alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-264047 |
| Document: axsm-20260605.htm | 0001193125-26-264047 |
| Document: 0001193125-26-264047-index-headers.html | 0001193125-26-264047 |
| Document: 0001193125-26-264047-index.html | 0001193125-26-264047 |
| Document: 0001193125-26-264047.txt | 0001193125-26-264047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $179.25 (−16.50%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $179.25 (−18.85%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $179.25 (−18.85%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $179.25 (−24.54%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $179.25 (−28.00%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $179.25 (−28.23%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $179.25 (−26.63%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $179.25 (−29.26%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $179.25 (−29.75%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $179.25 (−29.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access